Scientists hunt for clues to speed up CMT drug trials

NCT ID NCT06794489

First seen Mar 09, 2026 · Last updated Jun 23, 2026 · Updated 16 times

Summary

This study follows 75 people with CMT1A and 25 healthy volunteers over five years to track how the disease changes over time. Researchers will analyze blood and skin samples to find biomarkers that could make future therapy trials more effective. The goal is not to test a treatment, but to develop better tools for measuring whether new treatments actually work.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMT1A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Medical Centre

    RECRUITING

    Göttingen, Lower Saxony, 37075, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could identify reliable biomarkers and outcome measures that make future clinical trials for CMT therapies faster and more accurate.

What could go wrong

This is an observational study, not a treatment trial. It will not directly improve symptoms, and the biomarkers identified may still fail to predict disease progression in larger or longer studies.

Conditions

The condition(s) this trial relates to.

Charcot-Marie-Tooth disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.